Hypoxia Signaling Pathway Analysis
Corresponding Organization : Ottawa Hospital
Other organizations : Kansas City University, Health Canada
Variable analysis
- Treatment with DMSO (vehicle)
- Treatment with cisplatin (5 µM)
- Treatment with metformin (25 µM)
- Treatment with gefitinib (5 µM)
- Different combinations of the above treatments
- Firefly luciferase activity
- Renilla luciferase activity
- MDA-MB-231 TNBC cells
- 24-well plates
- Transfection with 500 ng of ODD-Luciferase-pcDNA3 or HRE-luciferase in conjunction with 500 ng Renilla pRL-SV40P construct
- Transfection using Lipofectamine 2000
- Treatment duration of 24 h
- Dual-Luciferase® Reporter Assay System (Promega)
- Not specified
- DMSO (vehicle)
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!